Iron deficiency injectables are the drugs which are prescribed for treating iron deficiency and delivered by intravenous (IV) infusion in the body. These IV drugs offer numerous benefits over oral medications by guaranteeing faster absorption of the infused supplements. Iron-deficiency anaemia is a disorder in which the blood does not have enough healthy red blood cells due to the deficiency of iron. For treating these patiets, these injectables are used. It is used only for the treatment of patients who cannot be treated appropriately with oral iron supplements.
Iron deficiency injectables also aid in overcoming poor adherence, non-compliance, and adverse gastrointestinal effects of oral medicines. Increasing number of patients undergoing dialysis, growing incidence of elderly population globally, growing expenditure on medications, increasing incidences of iron deficiency anaemia are some of the major factors that are likely to boost the growth of the market. Data Bridge Market Research analyses a growth rate in the iron deficiency injectable market in the forecast period 2023-2030.
The expected CAGR of the iron deficiency injectable market tends to be around 9.20% in the mentioned forecast period. The market was valued at USD 11.12 billion in 2022 and would grow to USD 22.5 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific has been witnessing positive growth for the iron deficiency injectable market throughout the forecasted period due to the surging levels of investment the government for the growth of the biopharmaceutical and biotechnology industry along with development of novel drugs and innovative medical treatment in the region.
Request a Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-iron-deficiency-injectable-market
North America dominates the market due to rising number of applications in cancer research along with adoption of low cost drugs in clinical diagnostics and development of research laboratories in the region.
Key players operating in the iron deficiency injectable market include:
AbbVie Inc. (U.S.)
Covis Pharma GmbH (U.S.)
DAIICHI SANKYO COMPANY, LIMITED (Japan)
Fresenius Kabi AG (Germany)
Vifor Pharma Management Ltd.(Switzerland)
PHARMACOSMOS A/S (Denmark)
Shield Therapeutics plc (U.K.)
American Regent, Inc. (U.S.)
Rockwell Medical, Inc. (U.S.)
Apotex Inc (Canada)
Bayer AG (Germany)
Akebia Therapeutics, Inc. (U.S.)
GSK plc (U.K.)
Novartis AG (Switzerland)
Aetna Inc.(U.S.)
Pfizer Inc (U.S.)
Systacare Remedies (India)
BSA Pharma Inc. (India)
Related Reports:
Iron-Deficiency Anemia Therapy Market https://www.databridgemarketresearch.com/reports/global-iron-deficiency-anemia-therapy-market
Iodine Deficiency Drug Market https://www.databridgemarketresearch.com/reports/global-iodine-deficiency-drug-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
According to the report, the global iron deficiency anemia treatment market was valued at US$ 9.2 Bn in 2019 and is projected to expand at a CAGR of ~9% from 2020 to 2030.
Iron deficiency anemia is a common type of nutritional anemia and considered a major public health problem globally.
It results in low level of hemoglobin in the blood.
Moreover, a study conducted for national primary care database in Germany, Belgium, Spain, and Italy, states that the annual incidence rate of iron deficiency anemia ranged from 7.2 to 13.9 per 1,000 person-years.Ferrous Sulfate to Dominate Global MarketIn terms of drug type, the global iron deficiency anemia treatment market has been classified into ferrous sulfate, ferrous gluconate, ferrous fumerate, ferric hydroxide, sodium ferric gluconate, iron carbohydrates, and others.
The availability in generic form, low cost, and higher preference in the treatment of iron deficiency anemia is anticipated to boost the ferrous sulfate segment.Request COVID Analysis on Iron Deficiency Anemia Treatment Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=81221Tablets to be Preferred Dosage FormIn terms of dosage form, the global iron deficiency anemia treatment market has been categorized into tablets, capsules, and liquid.
Tablet is the most stable, inexpensive, and widely available dosage form for the treatment of iron deficiency anemia.
